查看購物車
  • Simplified Chinese
  • English
  • Japanese
2021-2031年亞太地區胃腸藥物市場報告（範圍、細分、動態和競爭分析）
市場調查報告書
商品編碼
1819725

2021-2031年亞太地區胃腸藥物市場報告（範圍、細分、動態和競爭分析）

Asia Pacific Gastrointestinal Drugs Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 165 Pages | 訂單完成後即時交付

價格

亞太地區胃腸藥物市場預計將大幅成長，到 2031 年將達到 223.777 億美元，高於 2023 年的 121.4518 億美元。這一成長代表著 2023 年至 2031 年的年複合成長率(CAGR) 為 7.9%。

執行摘要和市場分析

亞太地區涵蓋多個主要國家，包括中國、日本、印度、澳洲、韓國等。中國和印度龐大的人口規模，以及製藥公司對該地區日益成長的興趣，推動著市場的成長。此外，胃腸道疾病發生率的上升、醫療支出的增加以及醫療技術的進步，也進一步推動了胃腸道藥物市場的發展。

市場區隔分析

亞太地區的胃腸藥物市場可根據藥物類別、應用、給藥途徑和配銷通路進行細分：

1. 藥品類別：市場分為幾類，包括生物製劑、止瀉藥和瀉藥、酸中和劑、抗發炎藥、止吐藥和止吐藥等。 2023年，生物製劑佔據了最大的市場。

2. 應用：市場也按應用細分，包括腸躁症 (IBS)、發炎性潰瘍性結腸炎、克隆氏症、胃腸炎、乳糜瀉等疾病。 2023 年，IBS 細分市場佔據最大佔有率。

3. 給藥途徑：市場分為口服和非注射給藥途徑。 2023年，口服給藥領域佔市場主導地位。

4.配銷通路：分銷管道包括醫院藥房、零售藥房和線上藥房，其中醫院藥房在2023年佔據最大的市場佔有率。

市場展望

全球胃腸道疾病的發生率正在上升，這促使人們加大對旨在開發新治療方法的研究資金投入。例如，耶魯大學醫學院每年從美國國家糖尿病、消化和腎臟疾病研究所（NIDDK）獲得超過800萬美元的資助，用於探索各種胃腸道疾病，包括發炎性腸道疾病（IBD）和肝病。同樣，北卡羅來納大學醫學院每年也獲得超過2000萬美元的資助，用於專注於胃腸道和肝病的研究，這凸顯了了解這些疾病並開發新療法的重要性。

臨床研究的最新進展，尤其是人工智慧 (AI) 的整合，正在改變胃腸醫學的模式。 AI 擴大用於分析大型資料集，從而帶來更個人化和有效的治療方案。機器學習演算法可以識別治療反應的預測標記，從而為個別患者制定最佳化的治療策略。

人工智慧也在增強胃腸醫學的診斷影像。透過運用深度學習演算法，研究人員可以高精度地分析醫學影像，例如CT掃描和內視鏡影像，有助於早期發現胃腸道異常。例如，人工智慧在大腸鏡檢查中診斷結直腸息肉方面已顯示出良好的前景，並有望減少不必要的手術干預。在紐卡斯爾永久慈善基金會等機構的資助下，研究人員正在探索人工智慧在開發發炎性腸道疾病（IBD）和潰瘍性結腸炎新療法中的應用，並專注於腸道微生物群和腸道幹細胞。

對新藥開發和基於人工智慧的方法的研究投入不斷增加，有望為胃腸道疾病帶來創新的治療方案，塑造胃腸道藥物市場的未來趨勢。

國家洞察

亞太胃腸藥物市場的特點是各國做出了巨大貢獻，其中中國將在 2023 年引領市場。中國的成長可歸因於其龐大的人口、胃腸疾病盛行率的上升、藥品銷售額的增加以及支持性的監管框架。

中國正積極加強醫療基礎建設，並開發各種醫藥產品。最近的一項研究表明，中國腸躁症（IBS）的盛行率為3.2%至17.7%，凸顯了胃腸道疾病給中國帶來的沉重負擔。為此，中國政府實施了中國胃腸道健康指數（GHI）等舉措，以監測和控制這些疾病的發生率，旨在提高預期壽命並改善醫療資源分配。

本土和國際製藥公司在中國的佈局正在促進市場成長。例如，2023年9月，EA Pharma Co., Ltd. 和 TransThera Sciences, Inc. 宣佈建立策略夥伴關係，共同開發針對胃腸道發炎疾病的先進療法，彰顯了其在該領域創新的決心。

公司簡介

亞太胃腸藥物市場的主要參與者包括賽諾菲公司、葛蘭素史克公司、強生公司、博士倫健康公司、阿斯特捷利康公司、武田製藥有限公司、艾伯維公司、拜耳公司和輝瑞公司。這些公司正在推行各種策略，包括擴張、產品創新和併購，以增強其市場佔有率並為消費者提供創新解決方案。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：亞太胃腸藥物市場－主要市場動態

  • 市場促進因素
    • 胃腸道疾病病例增加
    • 生物製劑的不斷發展
  • 市場限制
    • 生物製劑成本高
    • 治療嚴重潰瘍性結腸炎或克隆氏症的生物製劑平均費用
  • 市場機會
    • 公司的策略舉措
  • 未來趨勢
    • 加大對新藥開發與人工智慧技術的研究投入
  • 促進因素和限制因素的影響：

第5章：胃腸藥物市場－亞太地區分析

  • 2021-2031年亞太地區胃腸藥物市場收入

第6章：亞太胃腸藥物市場分析－依藥物類別

  • 生物製劑
  • 止瀉藥和瀉藥
  • 酸中和劑
  • 抗發炎藥物
  • 止吐藥和止噁心藥
  • 其他

第7章：亞太胃腸藥物市場分析-按應用

  • 急躁性腸症候群
  • 發炎性潰瘍性結腸炎
  • 克隆氏症
  • 胃腸炎
  • 乳糜瀉
  • 其他

第8章：亞太胃腸藥物市場分析－依給藥途徑

  • 口服
  • 腸外

第9章：亞太胃腸藥物市場分析-按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第10章：亞太胃腸藥物市場－國家分析

  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區

第 11 章：產業格局

  • 概述
  • 亞太胃腸藥物市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第12章：公司簡介

  • Sanofi SA
  • GSK Plc
  • Johnson & Johnson
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • Takeda Pharmaceutical Co Ltd
  • AbbVie Inc
  • Bayer AG
  • Celltrion Inc
  • Pfizer Inc

第 13 章：附錄

Product Code: TIPRE00016279

The Asia Pacific gastrointestinal drugs market is projected to grow significantly, reaching an estimated US$ 22,377.77 million by 2031, up from US$ 12,145.18 million in 2023. This growth represents a compound annual growth rate (CAGR) of 7.9% from 2023 to 2031.

Executive Summary and Market Analysis

The Asia Pacific region encompasses several key countries, including China, Japan, India, Australia, South Korea, and others. The substantial populations in China and India, along with the increasing interest from pharmaceutical companies in this region, are driving market growth. Additionally, the rising incidence of gastrointestinal disorders, increased healthcare expenditure, and advancements in medical technology are further propelling the gastrointestinal drugs market.

Market Segmentation Analysis

The gastrointestinal drugs market in Asia Pacific can be segmented based on drug class, application, route of administration, and distribution channel:

1. Drug Class: The market is divided into several categories, including biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, among others. In 2023, biologics accounted for the largest market share.

2. Application: The market is also segmented by application, which includes conditions such as irritable bowel syndrome (IBS), inflammatory ulcerative colitis, Crohn's disease, gastroenteritis, celiac disease, and others. The IBS segment held the largest share in 2023.

3. Route of Administration: The market is bifurcated into oral and parenteral routes. The oral administration segment dominated the market in 2023.

4. Distribution Channel: The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies holding the largest market share in 2023.

Market Outlook

The prevalence of gastrointestinal diseases is on the rise globally, prompting increased funding for research aimed at developing new treatment methods. For example, the Yale School of Medicine receives over US$ 8 million annually from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to explore various gastrointestinal disorders, including inflammatory bowel disease (IBD) and liver diseases. Similarly, the UNC School of Medicine has over US$ 20 million in annual funding for research focused on gastrointestinal and liver diseases, emphasizing the importance of understanding these conditions and developing new therapies.

Recent advancements in clinical research, particularly the integration of artificial intelligence (AI), are transforming the landscape of gastrointestinal medicine. AI is increasingly utilized to analyze large datasets, leading to more personalized and effective treatment options. Machine learning algorithms can identify predictive markers for treatment responses, allowing for optimized therapeutic strategies tailored to individual patients.

AI is also enhancing diagnostic imaging in gastrointestinal medicine. By employing deep learning algorithms, researchers can analyze medical images, such as CT scans and endoscopic images, with high precision, facilitating early detection of gastrointestinal abnormalities. For instance, AI has shown promise in diagnosing colorectal polyps during colonoscopy, potentially reducing unnecessary surgical interventions. With funding from organizations like the Newcastle Permanent Charitable Foundation, researchers are exploring AI applications in developing new therapies for IBD and ulcerative colitis, focusing on the gut microbiome and intestinal stem cells.

The increasing investment in research for novel drug development and AI-based methodologies is expected to introduce innovative treatment solutions for gastrointestinal conditions, shaping future trends in the gastrointestinal drugs market.

Country Insights

The Asia Pacific gastrointestinal drugs market is characterized by significant contributions from various countries, with China leading the market in 2023. The growth in China can be attributed to its large population, the rising prevalence of gastrointestinal diseases, increasing pharmaceutical sales, and supportive regulatory frameworks.

China is actively enhancing its healthcare infrastructure and developing various medicinal products. A recent study indicated that the prevalence of irritable bowel syndrome (IBS) in China ranges from 3.2% to 17.7%, highlighting the substantial burden of gastrointestinal diseases in the country. In response, the Chinese government has implemented initiatives like the China Gastrointestinal Health Index (GHI) to monitor and control the incidence of these diseases, aiming to improve life expectancy and healthcare resource distribution.

The presence of both local and international pharmaceutical companies in China is fostering market growth. For instance, in September 2023, EA Pharma Co., Ltd. and TransThera Sciences, Inc. announced a strategic collaboration to develop advanced therapeutics targeting inflammatory diseases of the gastrointestinal system, showcasing the commitment to innovation in this sector.

Company Profiles

Key players in the Asia Pacific gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, and Pfizer Inc. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Asia Pacific Gastrointestinal Drugs Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Cases of Gastrointestinal Diseases
    • 4.1.2 Increasing Development of Biologics
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Biologics
    • 4.2.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
  • 4.3 Market Opportunities
    • 4.3.1 Strategic Initiatives by Companies
  • 4.4 Future Trends
    • 4.4.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
  • 4.5 Impact of Drivers and Restraints:

5. Gastrointestinal Drugs Market - Asia Pacific Analysis

  • 5.1 Asia Pacific Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031

6. Asia Pacific Gastrointestinal Drugs Market Analysis - by Drug Class

  • 6.1 Biologics
    • 6.1.1 Overview
    • 6.1.2 Biologics: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Antidiarrheal and Laxatives
    • 6.2.1 Overview
    • 6.2.2 Antidiarrheal and Laxatives: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Acid Neutralizers
    • 6.3.1 Overview
    • 6.3.2 Acid Neutralizers: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Anti-inflammatory Drugs
    • 6.4.1 Overview
    • 6.4.2 Anti-inflammatory Drugs: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Antiemetic and Antinauseants
    • 6.5.1 Overview
    • 6.5.2 Antiemetic and Antinauseants: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Gastrointestinal Drugs Market Analysis - by Application

  • 7.1 Irritable Bowel Syndrome
    • 7.1.1 Overview
    • 7.1.2 Irritable Bowel Syndrome: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Inflammatory Ulcerative Colitis
    • 7.2.1 Overview
    • 7.2.2 Inflammatory Ulcerative Colitis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Crohn's Disease
    • 7.3.1 Overview
    • 7.3.2 Crohn's Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Gastroenteritis
    • 7.4.1 Overview
    • 7.4.2 Gastroenteritis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Celiac Disease
    • 7.5.1 Overview
    • 7.5.2 Celiac Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Gastrointestinal Drugs Market Analysis - by Route of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Parenteral
    • 8.2.1 Overview
    • 8.2.2 Parenteral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Gastrointestinal Drugs Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Online Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Gastrointestinal Drugs Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.1 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.1.2 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.1.3 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.1.4 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.2 Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.2.2 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.2.3 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.2.4 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.3 India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.3.2 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.3.3 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.3.4 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.4 Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.4.2 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.4.3 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.4.4 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.5 South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.1 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.5.2 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.5.3 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.5.4 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.6 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.1 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.6.2 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.6.3 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.6.4 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Asia Pacific Gastrointestinal Drugs Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Sanofi SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 GSK Plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Johnson & Johnson
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Bausch Health Companies Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 AstraZeneca Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Takeda Pharmaceutical Co Ltd
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AbbVie Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Bayer AG
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Celltrion Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Pfizer Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Asia Pacific Gastrointestinal Drugs Market Segmentation
  • Table 2. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 4. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 8. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 12. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 15. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 16. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 17. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 18. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 19. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 20. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 21. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 23. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 24. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 25. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. Recent Organic Growth Strategies in Asia Pacific Gastrointestinal Drugs Market
  • Table 27. Recent Inorganic Growth Strategies in the Asia Pacific Gastrointestinal Drugs Market
  • Table 28. Glossary of Terms, Asia Pacific Gastrointestinal Drugs Market

List Of Figures

  • Figure 1. Asia Pacific Gastrointestinal Drugs Market Segmentation, by Country
  • Figure 2. Asia Pacific Gastrointestinal Drugs Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Asia Pacific Gastrointestinal Drugs Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 6. Biologics: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Antidiarrheal and Laxatives: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Acid Neutralizers: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Anti-inflammatory Drugs: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Antiemetic and Antinauseants: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Asia Pacific Gastrointestinal Drugs Market Share (%) - by Application (2023 and 2031)
  • Figure 13. Irritable Bowel Syndrome: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Inflammatory Ulcerative Colitis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Crohn's Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Gastroenteritis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Celiac Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Asia Pacific Gastrointestinal Drugs Market Share (%) - by Route of Administration (2023 and 2031)
  • Figure 20. Oral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Parenteral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Asia Pacific Gastrointestinal Drugs Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 23. Hospital Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Online Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Asia Pacific Gastrointestinal Drugs Market Breakdown, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 27. Asia Pacific Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 28. China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Growth Strategies in Asia Pacific Gastrointestinal Drugs Market